Overview
Cough variant asthma (CVA) is a clinical presentation characterized primarily by a persistent cough without the typical respiratory symptoms of wheezing or shortness of breath. This condition predominantly affects children but can also manifest in adults. The high prevalence of cough and cold medication use among young children highlights the commonality of respiratory symptoms in this age group, often complicating the diagnosis and management of CVA [PMID:18676518]. Understanding the epidemiology, clinical presentation, diagnostic approaches, and management strategies is crucial for effective patient care. This guideline synthesizes evidence from various studies to provide a comprehensive clinical reference for clinicians dealing with CVA.
Epidemiology
The epidemiology of cough variant asthma underscores the significant burden of respiratory symptoms, particularly in pediatric populations. In the United States, it is observed that approximately 10.1% of children use cough and cold medications weekly, with a notable trend towards higher exposure among 2- to 5-year-olds to decongestants, first-generation antihistamines, and antitussives [PMID:18676518]. This frequent use of symptomatic treatments can mask underlying conditions like CVA, making accurate diagnosis challenging. Additionally, the heterogeneous nature of pediatric cough, as highlighted by recent research, indicates that symptoms often intertwine with other respiratory issues, complicating clinical assessment [PMID:31495906]. Understanding these patterns is essential for clinicians to recognize and address the multifaceted nature of cough presentations in children and adults alike.
Clinical Presentation
The clinical presentation of cough variant asthma is primarily characterized by a chronic cough that can significantly interfere with daily activities. In adults, studies have developed prediction models such as the RISSC85 rule, which incorporates factors like baseline risk, impact on daily life, smoking history, sputum characteristics, presence of crackles, and blood pressure to predict poor outcomes in acute cough cases [PMID:29632005]. While this model is more applicable to acute cough scenarios, it underscores the importance of comprehensive symptom assessment in CVA. For pediatric patients, the complexity of symptom networks is particularly pronounced, with cough often intertwined with other respiratory symptoms, affecting both diagnosis and treatment response [PMID:31495906]. Cho et al. emphasize the utility of detailed assessments, including cough-specific quality of life measures and subjective severity scales, which are vital for a thorough clinical evaluation [PMID:30928483]. Electronic monitoring devices have shown promise in objectively assessing cough frequency but may not fully capture the subjective impact on patients, as evidenced by variable correlations with visual analog scales and quality-of-life questionnaires [PMID:23928647]. Clinicians must therefore integrate both objective measurements and patient-reported outcomes to gain a comprehensive understanding of the patient's condition.
Diagnosis
Diagnosing cough variant asthma requires a multifaceted approach that combines clinical judgment with objective measures. The RISSC85 model, while primarily designed for acute cough, demonstrates moderate sensitivity (62%) and specificity (59%) in predicting poor outcomes, suggesting its potential utility in identifying high-risk patients [PMID:29632005]. However, for CVA specifically, objective techniques such as measuring cough reflex sensitivity have emerged as valuable diagnostic tools [PMID:30928483]. These methods can help differentiate CVA from other causes of chronic cough, such as gastroesophageal reflux disease (GERD) or upper airway cough syndrome (UACS). Additionally, validated instruments like the Leicester Cough Questionnaire (LCQ) and the Cough Quality of Life Questionnaire (CQLQ) provide reliable assessments of cough impact in both adults and adolescents, aiding in the comprehensive evaluation of CVA [PMID:23928647]. Clinicians should consider these tools alongside clinical history and physical examination to refine diagnostic accuracy and tailor management strategies accordingly.
Management
The management of cough variant asthma focuses on addressing both the underlying airway inflammation and the symptomatic cough. Identifying patients at higher risk of poor outcomes using predictive models like RISSC85 can guide judicious use of additional diagnostic tests and avoid unnecessary interventions such as overprescribing antibiotics [PMID:29632005]. In pediatric populations, interventions that target a broader range of symptoms within the complex symptom network have shown promise in improving treatment outcomes [PMID:31495906]. Cho et al. suggest that detailed assessments can predict patient responses to both pharmacological (e.g., inhaled corticosteroids, bronchodilators) and nonpharmacological treatments (e.g., lifestyle modifications, environmental controls), thereby optimizing management strategies [PMID:30928483]. For children, tools like the Parent Cough-Specific Quality of Life questionnaire offer valid and reliable methods for monitoring treatment efficacy and adjusting interventions as needed [PMID:23928647]. Given the limited evidence on the efficacy and potential adverse effects of certain medications, especially in young children, clinicians are advised to explore safer alternatives for managing cough and cold symptoms [PMID:18676518]. This includes prioritizing non-pharmacological interventions and carefully selecting medications based on individual patient profiles.
Prognosis & Follow-up
The prognosis of cough variant asthma varies widely depending on the effectiveness of management strategies and adherence to treatment plans. Consistent monitoring using comprehensive cough assessment methods is crucial for tracking disease progression and treatment efficacy [PMID:30928483]. Regular follow-up appointments should include reassessment of cough frequency, severity, and impact on quality of life, utilizing both objective measures and patient-reported outcomes. This ongoing evaluation allows clinicians to make timely adjustments to treatment regimens, ensuring optimal symptom control and minimizing the risk of complications. In particular, monitoring for signs of asthma exacerbations or the development of other respiratory conditions is essential for maintaining long-term respiratory health in patients with CVA.
Special Populations
Special considerations are necessary when managing cough variant asthma in vulnerable populations, such as infants, elderly patients, and those in palliative care settings. Detailed cough assessments are particularly valuable in these groups due to their reduced airway protection and unique symptom presentations [PMID:30928483]. For instance, in palliative care, where cough can significantly impact quality of life, a nuanced approach that integrates symptom management with supportive care is crucial. Clinicians must be vigilant in recognizing the specific challenges these populations face and tailor interventions to address both the cough and associated comorbidities effectively. Understanding these nuances can lead to more personalized and compassionate care strategies for individuals with CVA in special populations.
Key Recommendations
References
1 Bruyndonckx R, Hens N, Verheij TJ, Aerts M, Ieven M, Butler CC et al.. Development of a prediction tool for patients presenting with acute cough in primary care: a prognostic study spanning six European countries. The British journal of general practice : the journal of the Royal College of General Practitioners 2018. link 2 Huang M, Wang J, Zhang R, Ni Z, Liu X, Liu W et al.. Symptom network topological features predict the effectiveness of herbal treatment for pediatric cough. Frontiers of medicine 2020. link 3 Cho PSP, Birring SS, Fletcher HV, Turner RD. Methods of Cough Assessment. The journal of allergy and clinical immunology. In practice 2019. link 4 Schmit KM, Coeytaux RR, Goode AP, McCrory DC, Yancy WS, Kemper AR et al.. Evaluating cough assessment tools: a systematic review. Chest 2013. link 5 Vernacchio L, Kelly JP, Kaufman DW, Mitchell AA. Cough and cold medication use by US children, 1999-2006: results from the slone survey. Pediatrics 2008. link
5 papers cited of 6 indexed.